Biotech Active Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Gilead Sciences Inc. (NASDAQ:GILD), MannKind Corp. (NASDAQ:MNKD), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naive genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. One hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.On Monday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed at $11.66. Company’s EPS growth for next 5 years is recorded as 17.58%.

On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company’s Board of Directors has authorized a dividend program under which the company intends to pay quarterly dividends of $0.43 per share, beginning in the second quarter of 2015, subject to quarterly declarations by the Board of Directors. The Board of Directors also approved the repurchase of up to an additional $15.0 billion of the company’s common stock. This new program is in addition to the currently authorized three-year $5.0 billion repurchase program (authorized in May 2014). Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity decreased -0.59% to close at $96.90. Company weekly performance is -8.75% while its quarterly performance stands at -9.39%. Gilead Sciences Inc. (NASDAQ:GILD) is -17.06% away from its 52 week high.

On 3 February, Sanofi and MannKind Corporation (NASDAQ:MNKD) announced that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. On last trading day MannKind Corp. (NASDAQ:MNKD) increased 7.75% to close at $7.51. Its volatility for the week is 6.21% while volatility for the month is 5.40%. MNKD’s EPS growth for past 5 years was 26.50%. MannKind Corp. (NASDAQ:MNKD) monthly performance is 29.93%.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will present at the Leerink Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Thursday, February 12, at 3:30 p.m. (ET). Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has 1.90% insider ownership while its institutional ownership stands at 68.20%. In last trading activity company’s stock closed at $6.85.

Leave a Reply

Your email address will not be published.